CD8A and synovial sarcoma: Moreover, the viability of CD8+ALDHhigh cells in the presence of adriamycin, a standard chemotherapeutic drug for osteosarcoma and synovial sarcoma, was higher than that of CD8+ALDHlow cells (Fig. 1D; Fig. S1D).